BE Therapeutics is engineering precursor tissue that mimics embryonic brain tissue to replace damaged neocortical and spinal cord tissue, facilitating normal maturation and integration post-transplantation. This technology aims to restore lost functions in individuals affected by stroke, trauma, neurodegeneration, and aging, addressing the current lack of effective treatments for central nervous system damage.
Funding
Funding not disclosed
Founders
Product
Problem
Damage to the central nervous system (CNS) from stroke, trauma, neurodegeneration, and aging results in permanent loss of function. Current treatments are unable to restore lost functions in individuals with CNS damage.
Solution
BE Therapeutics is developing engineered precursor tissue that mimics embryonic brain tissue to replace damaged neocortical and spinal cord tissue. The engineered tissue contains the proper cell types, signaling cues, and structure to facilitate normal maturation and integration post-transplantation. This technology aims to restore lost functions by replacing damaged tissue with functional tissue that can integrate with the host and encode useful information for the patient. The initial focus is on replacing damaged neocortical tissue, followed by other parts of the CNS.
Target Audience
The primary target audience includes individuals affected by stroke, trauma, neurodegeneration, and aging who have experienced damage to the central nervous system.
Features
- Engineered precursor tissue mimicking embryonic brain tissue
- Multi-cell type structured brain tissue
- Tissue designed to mature normally after transplantation
- Tissue designed to integrate with the host
- Focus on replacing damaged neocortical tissue initially